Penka Petrova is Chief Development Officer at Trillium Therapeutics Inc. (TRIL). They have made 3 open-market trades across 1 company since 2021, most recently 2021-04-08.
CIK 0001838044
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TRIL | 5,312 | $103K |
Shares reported on the most recent Form 4, priced at the 2021-04-09 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TRIL | SELL | 2021-04-08 | 2021-04-09 | $11.09 | $118K | -7.8% | -11.6% | -17.7% |
| TRIL | SELL | 2021-03-10 | 2021-03-12 | $11.08 | $118K | -19.2% | -19.1% | -20.5% |
| TRIL | SELL | 2021-02-08 | 2021-02-10 | $12.72 | $142K | -11.5% | -10.9% | -32.5% |
| TRIL | SELL · 10b5-1 | 2021-01-11 | 2021-01-13 | $15.21 | $8K | -15.0% | -9.4% | -31.0% |
| TRIL | SELL · 10b5-1 | 2021-01-08 | 2021-01-12 | $15.50 | $40K | -10.2% | -7.6% | -31.1% |
| TRIL | SELL · 10b5-1 | 2021-01-07 | 2021-01-11 | $14.71 | $40K | -11.9% | -8.7% | -32.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.